Pharmacodynamics of Antimalarial Chemoprevention
Overall, the primary goal of this project is to optimize dosing regimens for IPT with DHA/PQ in pregnant women and children to enable protection against malaria without the selection of drug resistance.
The specific aims are:
- to define the PKs of DHA/PQ when used as IPT for Ugandan pregnant women and children
- to characterize associations between exposure to PQ and circulating parasitemia, placental malaria, and clinical malaria in pregnant women and children
- to characterize associations between exposure to DHA and PQ and risk of altered drug sensitivity.
Malaria is one of the most important infectious diseases in the world, available control measures are inadequate, and a promising new control strategy is intermittent administration of full treatment doses of dihydroartemisinin/piperaquine (DHA/PQ) to all at-risk individuals. However, optimal dosing strategies for this regimen have not been established, especially for children and pregnant women, the groups at highest risk of malaria. This project will leverage a recently funded clinical trial studying the preventive efficacy of DHA/PQ to evaluate the impacts of drug levels on risks of malaria and selection of drug-resistant parasites, and thereby inform regarding optimal dosing regimens of DHA/PQ to prevent malaria in high risk groups.